Peixuan Guo
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
389
Citations
16,977
Est. group size
~7
Recurring co-author estimate
Active years
40
Publishing since 1986
Peixuan Guo's research centers on RNA nanotechnology, particularly the use of a bacterial virus (phi29 bacteriophage) motor RNA (pRNA) to build nanoscale particles that can deliver drugs, small RNAs, and other therapeutic molecules to diseased cells, especially cancer. Much of the recent work applies these RNA nanoparticle and extracellular vesicle delivery systems to targeted treatment of breast, prostate, and liver cancers, alongside some studies on ocular drug delivery and biomarkers in cancer.
Publication output has fluctuated over the past decade, peaking around 2022-2023 (30+ papers/year) before declining somewhat in 2024-2025, with an average of about 18 papers per year over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients
Biomarker Research · 2025
- Exploring the correlation between Drp1 protein and the neurotoxicity of propofol
Frontiers in Neuroscience · 2025
- Constructing an active chimeric pRNA ring with a stoichiometry of six and identifying 12 domains of the pRNA ring binding to the 12-subunit channel of phi29 DNA-packaging motor
RNA · 2025
- Synergistic RNA particles for spontaneous and specific cancer targeting but low toxicity due to motility and deformation
Nanomedicine · 2025
- Retraction Note: Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion
Oncogene · 2025
- Illustration of the Evolution Tracking and Origin of Organisms by Comparing the Variable 1d Sequences and Conserved 2d and 3d Structures of Different Ncrna Nanostructures
SSRN Electronic Journal · 2025
- Correction: Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients
Biomarker Research · 2025
- Illustration of the variable 1D sequences but conserved 2D and 3D structures of different ncRNA nanostructures for tracking the evolution and origin of organisms
Non-coding RNA Research · 2025
- pH-responsive bond as a linker for the release of chemical drugs from RNA–drug complexes in endosome or lysosome
RNA NanoMed · 2024
- Self-powered and charge-transport-layer-free photodetectors based on chloride treated perovskites for weak light detection
Science China Materials · 2024
- Engineered extracellular vesicles for combinatorial TNBC therapy: SR-SIM-guided design achieves substantial drug dosage reduction
Molecular Therapy · 2024
- Posterior eye delivery of angiogenesis-inhibiting RNA nanoparticles via subconjunctival injection
International Journal of Pharmaceutics · 2024
- Integrated Metabolome and Transcriptome Analyses Reveal the Mechanisms Regulating Flavonoid Biosynthesis in Blueberry Leaves under Salt Stress
Horticulturae · 2024
- RNA Nanotechnology for Codelivering High-Payload Nucleoside Analogs to Cancer with a Synergetic Effect
Molecular Pharmaceutics · 2024
- Targeted Delivery of Potent Chemical Drugs and RNAi to Drug-Resistant Breast Cancer Using RNA-Nanotechnology and RNA-Ligand Displaying Extracellular vesicles
RNA NanoMed · 2024
- ACS Nano×8
- Biomaterials×7
- Molecular Therapy×6
- Molecular Therapy — Nucleic Acids×6
- Nanomedicine Nanotechnology Biology and Medicine×6
- Yancheng Du
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Carlos E. Castro
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Wolfgang Pfeifer
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Anjelica Kucinic
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Xin Li
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile